Literature DB >> 24956507

The osteoporosis treatment gap.

John A Kanis1, Axel Svedbom, Nicholas Harvey, Eugene V McCloskey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24956507     DOI： 10.1002/jbmr.2301

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  46 in total

1.  Bisphosphonate drug holidays: we reap what we sow.

Authors:  S L Silverman; J D Adachi; E Dennison
Journal:  Osteoporos Int       Date:  2015-12-14       Impact factor: 4.507

Review 2.  Exercise for the prevention of osteoporosis in postmenopausal women: an evidence-based guide to the optimal prescription.

Authors:  Robin M Daly; Jack Dalla Via; Rachel L Duckham; Steve F Fraser; Eva Wulff Helge
Journal:  Braz J Phys Ther       Date:  2018-11-22       Impact factor: 3.377

Review 3.  Fracture liaison services: do they reduce fracture rates?

Authors:  Irma J A de Bruin; Caroline E Wyers; Joop P W van den Bergh; Piet P M M Geusens
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-04-27       Impact factor: 5.346

4.  Dysmobility Syndrome Independently Increases Fracture Risk in the Osteoporotic Fractures in Men (MrOS) Prospective Cohort Study.

Authors:  Bjoern Buehring; Karen E Hansen; Brian L Lewis; Steven R Cummings; Nancy E Lane; Neil Binkley; Kristine E Ensrud; Peggy M Cawthon
Journal:  J Bone Miner Res       Date:  2018-06-21       Impact factor: 6.741

5.  Screening Tests for Osteoporosis: Too Few for Some, Too Many for Others.

Authors:  Douglas C Bauer
Journal:  J Gen Intern Med       Date:  2015-12       Impact factor: 5.128

6.  Overdiagnosis of osteoporosis: fact or fallacy?

Authors:  J Compston
Journal:  Osteoporos Int       Date:  2015-07-02       Impact factor: 4.507

7.  FRAX and ethnicity.

Authors:  J A Kanis; C Cooper; B Dawson-Hughes; N C Harvey; H Johansson; M Lorentzon; E V McCloskey; J-Y Reginster; R Rizzoli
Journal:  Osteoporos Int       Date:  2020-09-04       Impact factor: 4.507

8.  Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial.

Authors:  C M Parsons; N Harvey; L Shepstone; J A Kanis; E Lenaghan; S Clarke; R Fordham; N Gittoes; I Harvey; R Holland; N M Redmond; A Howe; T Marshall; T J Peters; D Torgerson; T W O'Neill; E McCloskey; C Cooper
Journal:  Osteoporos Int       Date:  2019-10-12       Impact factor: 4.507

9.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2018-10-15       Impact factor: 4.507

Review 10.  Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women.

Authors:  Roland D Chapurlat
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-06       Impact factor: 5.346
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.